First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
|
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [31] Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis.
    Cheng, Ce
    Chineke, Iloabueke Gabriel
    McBride, Ali
    Chipollini, Juan
    Gelmann, Edward Paul
    Recio-Boiles, Alejandro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Cirillo, Alessio
    Marinelli, Daniele
    Romeo, Umberto
    Messineo, Daniela
    De Felice, Francesca
    De Vincentiis, Marco
    Valentini, Valentino
    Mezi, Silvia
    Valentini, Filippo
    Vivona, Luca
    Chiavassa, Antonella
    Cerbelli, Bruna
    Santini, Daniele
    Bossi, Paolo
    Polimeni, Antonella
    Marchetti, Paolo
    Botticelli, Andrea
    BMC CANCER, 2024, 24 (01)
  • [33] Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States
    Hale, Oliver
    Patterson, Karl
    Lai, Yizhen
    Meng, Yang
    Li, Haojie
    Godwin, James Luke
    Moreno, Blanca Homet
    Mamtani, Ronac
    CLINICAL GENITOURINARY CANCER, 2021, 19 (01) : E17 - E30
  • [34] Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience
    Hsu, Miles M.
    Xia, Yuhe
    Troxel, Andrea
    Delbeau, Daniela
    Francese, Kaitlyn
    Leis, Dayna
    Shepherd, Deneuve
    Balar, Arjun, V
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : E209 - E216
  • [35] Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma
    Bopota, Katerina
    Donnelly, Oliver
    Borumandi, Farzad
    JOURNAL OF CRANIOFACIAL SURGERY, 2023, 34 (03) : E247 - E249
  • [36] Benefit in patients with PD-L1-positive TNBC
    Diana Romero
    Nature Reviews Clinical Oncology, 2019, 16 : 6 - 6
  • [37] Benefit in patients with PD-L1-positive TNBC
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (01) : 6 - 6
  • [38] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
  • [39] Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Piperdi, Bilal
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (18) : 1541 - 1554
  • [40] First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features
    Fontes-Sousa, Mario
    Calvo, Emiliano
    CANCER TREATMENT REVIEWS, 2022, 105
12345